Federal Register #DEA-1641

DEA Notice: Temporary Scheduling of O-Desmethyltramadol (O-DSMT) as a Schedule I Substance

This notice from the Drug Enforcement Administration (DEA) announces a regulatory action regarding O-Desmethyltramadol (O-DSMT): - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - OEMs and Vendors: - No commercial OEMs or vendors are involved; DEA is the issuing agency - Products/Services Requested: - No products or services are being procured - The subject is O-Desmethyltramadol (O-DSMT), including its isomers, esters, ethers, salts, and related compounds - Unique or Notable Requirements: - DEA intends to temporarily place O-DSMT in Schedule I of the Controlled Substances Act - This action imposes strict regulatory controls and sanctions on handling O-DSMT - The decision is based on O-DSMT's high potential for abuse, lack of accepted medical use, and significant public health risks - The temporary scheduling will be effective for two years, with a possible one-year extension pending permanent scheduling - No procurement or acquisition activity is associated with this notice; it is strictly a regulatory measure

Description

The Drug Enforcement Administration (DEA) is issuing a notice of intent to publish a temporary order to place O-desmethyltramadol (O-DSMT), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, in Schedule I of the Controlled Substances Act. This temporary scheduling will impose regulatory controls and sanctions applicable to Schedule I substances on persons who handle or propose to handle O-DSMT. The action is taken due to the substance's high potential for abuse, lack of accepted medical use in the United States, and safety concerns. The temporary scheduling order is expected to be published on or after July 24, 2026.

View original listing